ONCOTHERAPY SCIENCE, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17 JPY | 0.00% |
|
-10.53% | -26.09% |
Valuation
| Fiscal Period: März | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 31,465 | 20,192 | 10,933 | 21,689 | 13,292 | 9,054 |
| Enterprise Value (EV) 1 | 24,725 | 15,335 | 6,220 | 18,790 | 11,456 | 7,937 |
| P/E ratio | -11 x | -6.79 x | -4.52 x | -13.9 x | -5.03 x | -8.1 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 149 x | 72.1 x | 34.6 x | 65.3 x | 11.5 x | 7.98 x |
| EV / Revenue | 117 x | 54.8 x | 19.7 x | 56.6 x | 9.94 x | 7 x |
| EV / EBITDA | -8.71 x | -5.98 x | -2.89 x | -11.8 x | -5.62 x | -7.28 x |
| EV / FCF | -10.9 x | -11.2 x | -4.01 x | -15.7 x | -6.43 x | -34.2 x |
| FCF Yield | -9.17% | -8.93% | -24.9% | -6.36% | -15.6% | -2.92% |
| Price to Book | 4.3 x | 4.2 x | 2.31 x | 7.05 x | 6.72 x | 10.6 x |
| Nbr of stocks (in thousands) | 147,032 | 149,572 | 176,332 | 176,332 | 192,644 | 192,644 |
| Reference price 2 | 214.0 | 135.0 | 62.00 | 123.0 | 69.00 | 47.00 |
| Announcement Date | 6/22/18 | 6/20/19 | 6/24/20 | 6/22/21 | 6/21/22 | 6/27/23 |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: März | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 211 | 280 | 316 | 332 | 1,153 | 1,134 |
| EBITDA 1 | -2,840 | -2,563 | -2,150 | -1,589 | -2,037 | -1,091 |
| EBIT 1 | -2,988 | -2,954 | -2,189 | -1,638 | -2,053 | -1,107 |
| Operating Margin | -1,416.11% | -1,055% | -692.72% | -493.37% | -178.06% | -97.62% |
| Earnings before Tax (EBT) 1 | -2,920 | -3,192 | -2,237 | -1,560 | -2,570 | -1,116 |
| Net income 1 | -2,851 | -2,934 | -2,238 | -1,561 | -2,571 | -1,118 |
| Net margin | -1,351.18% | -1,047.86% | -708.23% | -470.18% | -222.98% | -98.59% |
| EPS 2 | -19.39 | -19.89 | -13.73 | -8.853 | -13.71 | -5.803 |
| Free Cash Flow 1 | -2,268 | -1,369 | -1,551 | -1,196 | -1,782 | -231.9 |
| FCF margin | -1,075.12% | -489.02% | -490.86% | -360.17% | -154.56% | -20.45% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 6/22/18 | 6/20/19 | 6/24/20 | 6/22/21 | 6/21/22 | 6/27/23 |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: March | 2020 S1 | 2021 S1 | 2022 S1 | 2022 Q3 | 2023 Q1 | 2023 S1 | 2023 Q3 | 2024 Q1 | 2024 S1 | 2024 Q3 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 104 | 100 | 240 | 95 | 385 | 514 | 185 | 148 | 356 | 110 |
| EBITDA | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -1,218 | -838 | -948 | -762 | -307 | -618 | -286 | -386 | -694 | -278 |
| Operating Margin | -1,171.15% | -838% | -395% | -802.11% | -79.74% | -120.23% | -154.59% | -260.81% | -194.94% | -252.73% |
| Earnings before Tax (EBT) 1 | -1,256 | -755 | -1,228 | -909 | -277 | -612 | -299 | -399 | -709 | -276 |
| Net income 1 | -1,256 | -756 | -1,229 | -910 | -277 | -613 | -300 | -400 | -710 | -277 |
| Net margin | -1,207.69% | -756% | -512.08% | -957.89% | -71.95% | -119.26% | -162.16% | -270.27% | -199.44% | -251.82% |
| EPS 2 | -8.010 | -4.290 | -6.740 | -4.780 | -1.440 | -3.190 | -1.550 | -1.990 | -3.420 | -1.260 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/8/19 | 11/6/20 | 11/5/21 | 2/4/22 | 8/5/22 | 11/4/22 | 2/10/23 | 8/10/23 | 11/10/23 | 2/9/24 |
1JPY in Million2JPY
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 6,740 | 4,857 | 4,713 | 2,899 | 1,836 | 1,117 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -2,269 | -1,369 | -1,551 | -1,196 | -1,782 | -232 |
| ROE (net income / shareholders' equity) | -33.1% | -51.3% | -46.6% | -40% | -102% | -78.9% |
| ROA (Net income/ Total Assets) | -20.1% | -27.6% | -26.2% | -24.2% | -42.4% | -33% |
| Assets 1 | 14,208 | 10,638 | 8,551 | 6,447 | 6,064 | 3,390 |
| Book Value Per Share 2 | 49.80 | 32.10 | 26.80 | 17.40 | 10.30 | 4.430 |
| Cash Flow per Share 2 | 45.80 | 32.00 | 26.70 | 16.40 | 9.530 | 5.800 |
| Capex 1 | 408 | 71 | 130 | 43 | 456 | 4 |
| Capex / Sales | 193.36% | 25.36% | 41.14% | 12.95% | 39.55% | 0.35% |
| Announcement Date | 6/22/18 | 6/20/19 | 6/24/20 | 6/22/21 | 6/21/22 | 6/27/23 |
1JPY in Million2JPY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -26.09% | 23.5M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- 4564 Stock
- Financials OncoTherapy Science, Inc.
